109 related articles for article (PubMed ID: 24431895)
1. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients.
Lim YS; Lee JY; Lee D; Shim JH; Lee HC; Lee YS; Suh DJ
Antimicrob Agents Chemother; 2013 Jul; 57(7):3369-74. PubMed ID: 23650172
[TBL] [Abstract][Full Text] [Related]
3. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis.
Su QM; Ye XG
World J Gastroenterol; 2012 Nov; 18(43):6290-301. PubMed ID: 23180951
[TBL] [Abstract][Full Text] [Related]
4. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.
Yang SS; Cai CW; Ma XQ; Xu J; Yu CB
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):507-514. PubMed ID: 33051132
[TBL] [Abstract][Full Text] [Related]
6. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Huang Q; Zhou B; Cai D; Zong Y; Wu Y; Liu S; Mercier A; Guo H; Hou J; Colonno R; Sun J
Hepatology; 2021 Jan; 73(1):41-52. PubMed ID: 32189364
[TBL] [Abstract][Full Text] [Related]
7. Effects of dyslipidemia on E antigen seroconversion of patients with chronic hepatitis B treated by nucleoside (acid) analogs.
Xia Z; Zheng J; Zheng L; Zheng E; Zou Z; Sheng X; Wu J
Lipids Health Dis; 2021 Oct; 20(1):148. PubMed ID: 34717643
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Delaugerre C; Marcelin AG; Thibault V; Peytavin G; Bombled T; Bochet MV; Katlama C; Benhamou Y; Calvez V
Antimicrob Agents Chemother; 2002 May; 46(5):1586-8. PubMed ID: 11959607
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV).
Hann HW; Chae HB; Dunn SR
Hepatol Int; 2008 Jun; 2(2):244-9. PubMed ID: 19669311
[TBL] [Abstract][Full Text] [Related]
10. Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B.
Ying Y; Hu YK; Jin JL; Zhang JM; Zhang WH; Huang YX
BMC Gastroenterol; 2018 Apr; 18(1):45. PubMed ID: 29625557
[TBL] [Abstract][Full Text] [Related]
11. Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance.
Lim LG; Aung MO; Seet BL; Tan C; Dan YY; Lee YM; Sutedja DS; Fernandes M; Lee GH; Koay E; Lim SG
World J Gastroenterol; 2010 Oct; 16(37):4691-6. PubMed ID: 20872970
[TBL] [Abstract][Full Text] [Related]
12. Telbivudine: a new treatment for chronic hepatitis B.
Amarapurkar DN
World J Gastroenterol; 2007 Dec; 13(46):6150-5. PubMed ID: 18069753
[TBL] [Abstract][Full Text] [Related]
13. Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy.
Zhang XG; Miao J; Li MW; Jiang SP; Hu FQ; Du YZ
J Zhejiang Univ Sci B; 2008 Jun; 9(6):506-10. PubMed ID: 18543406
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis.
Yu W; Zhao C; Shen C; Wang Y; Lu H; Fan J
PLoS One; 2013; 8(6):e65952. PubMed ID: 23776577
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents.
Shin JH; Kwon HJ; Jang HR; Lee JE; Gwak GY; Huh W; Jung SH; Lee JH; Kim YG; Kim DJ; Oh HY
Medicine (Baltimore); 2016 Jan; 95(1):e2400. PubMed ID: 26735542
[TBL] [Abstract][Full Text] [Related]
16. [Role of mitochondrial autophagy and the curative effect of rehmannia glutinosa leaves total glycoside capsules on nucleos(t)ide drug-induced renal injury].
Zhong K; Zhang MM; Zhu ZX; Liao X; Zhang BF; Cheng ML
Zhonghua Gan Zang Bing Za Zhi; 2024 Feb; 32(2):125-132. PubMed ID: 38514261
[No Abstract] [Full Text] [Related]
17. What physicians should know about the management of chronic hepatitis B in children: East side story.
Choe HJ; Choe BH
World J Gastroenterol; 2014 Apr; 20(13):3582-9. PubMed ID: 24707141
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment.
Zhou XJ; Marbury TC; Alcorn HW; Smith WB; Dubuc Patrick G; Chao GC; Brown NA
Antimicrob Agents Chemother; 2006 May; 50(5):1721-6. PubMed ID: 16641441
[TBL] [Abstract][Full Text] [Related]
19. Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis.
Choi YH; Lee CH; Ko MS; Han HJ; Kim SG
Toxicol Res; 2017 Oct; 33(4):343-350. PubMed ID: 29071019
[TBL] [Abstract][Full Text] [Related]
20. Cluster-Randomized Trial to Increase Hepatitis B Testing among Koreans in Los Angeles.
Bastani R; Glenn BA; Maxwell AE; Jo AM; Herrmann AK; Crespi CM; Wong WK; Chang LC; Stewart SL; Nguyen TT; Chen MS; Taylor VM
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1341-9. PubMed ID: 26104909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
